
2025

[Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy.](#)

Cherradi S, Roux S, Dupuy M, Tabone-Eglinger S, Tuailon E, Zioli M, Assenat E, Duong HT.
Sci Rep. 2025 Jan 7;15(1):1179. doi: 10.1038/s41598-024-84304-4.

[Simultaneous Activation of Beta-Oxidation and De Novo Lipogenesis in MASLD-HCC: A New Paradigm.](#)

Fatima Dabhoul, Jihan Sun, Benjamin Buchard, Natali Abeywickrama-Samarakoon, Estelle Pujos-Guillot, Stéphanie Durand, Mélanie Petera, Delphine Centeno, Franscessa Guerrieri, Massimiliano Cocca, Massimo Levrero, Adrien Rossary, Delphine Weil, Vincent Di Martino, Aicha Demidem, Armando Abergel
Liver International (undergoing revision after peer review)

2024

[Hepatocellular carcinoma hosts cholinergic neural cells and tumoral hepatocytes harboring targetable muscarinic receptors.](#)

Hernandez CA, Verzeroli C, Roca-Suarez AA, Farca-Luna AJ, Tonon L, Esteban-Fabro R, Pinyol R, Plissonnier ML, Chicherova I, Dubois A, Bellaud P, Seffals M, Turlin B, Fautrel A, Ichim G, Rivoire M, Passot G, Macek-Jilkova Z, Decaens T, Viari A, Testoni B, Rebouissou S, Llovet JM, Zoulim F, Parent R.
JHEP Rep. 2024 Nov 12;7(1):101245. doi: 10.1016/j.jhepr.2024.101245.

2023

[Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.](#)

Calderaro J, Ghaffari Laleh N, Zeng Q, Maille P, Favre L, Pujals A, Klein C, Bazille C, Heij LR, Uguen A, Luedde T, Di Tommaso L, Beaufrère A, Chatain A, Gastineau D, Nguyen CT, Nguyen-Canh H, Thi KN, Gnemmi V, Graham RP, Charlotte F, Wendum D, Vij M, Allende DS, Aucejo F, Diaz A, Rivière B, Herrero A, Evert K, Calvisi DF, Augustin J, Leow WQ, Leung HHW, Boleslawski E, Rela M, François A, Cha AW, Forner A, Reig M, Allaire M, Scatton O, Chatelain D, Boulagnon-Rombi C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Gopal P, Brustia R, Vibert E, Schulze K, Rütther DF, Weidemann SA, Rhaïem R, Pawlotsky JM, Zhang X, Luciani A, Mulé S, Laurent A, Amaddeo G, Regnault H, De Martin E, Sempoux C, Navale P, Westerhoff M, Lo RC, Bednarsch J, Gouw A, Guettier C, Lequoy M, Harada K, Sripongpun P, Wetwittayaklang P, Loménié N, Tantipisit J, Kaewdech A, Shen J, Paradis V, Caruso S, Kather JN.
Nat Commun. 2023 Dec 14;14(1):8290.

[Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.](#)

Zeng Q, Klein C, Caruso S, Maille P, Allende DS, Mínguez B, Iavarone M, Ningarhari M, Casadei-Gardini A, Pedica F, Rimini M, Perbellini R, Boulagnon-Rombi C, Heurgué A, Maggioni M, Rela M, Vij M, Baulande S, Legoix P, Lameiras S; HCC-AI study group; Bruges L, Gnemmi V, Nault JC, Campani C, Rhee H, Park YN, Iñarrairaegui M, Garcia-Porrero G, Argemi J, Sangro B, D'Alessio A, Scheiner B, Pinato DJ, Pinter M, Paradis V, Beaufrère A, Peter S, Rimassa L, Di Tommaso L, Vogel A, Michalak S, Boursier J, Loménié N, Zioli M, Calderaro J.
Lancet Oncol. 2023 Dec;24(12):1411-1422. doi: 10.1016/S1470-2045(23)00468-0.

[Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome.](#)

Desert R, Chen W, Ge X, Viel R, Han H, Athavale D, Das S, Song Z, Lantvit D, Cano L, Naba A, Musso O, Nieto N. *Hepatology*. 2023 Sep 1;78(3):741-757. doi: 10.1097/HEP.0000000000000362.

[Metabolic Networks: Weighted Gene Correlation Network Analysis.](#)

Desquilles L, Musso O.
Methods Mol Biol 2023;2675:317-325

[Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome.](#)

Desert R, Chen W, Ge X, Viel R, Han H, Athavale D, Das S, Song Z, Lantvit D, Cano L, Naba A, Musso O, Nieto N.
Hepatology. 2023 Sep 1;78(3):741-757

2022

[Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.](#)

Beaufrère A, Caruso S, Calderaro J, Poté N, Bijot JC, Couchy G, Cauchy F, Vilgrain V, Zucman-Rossi J, Paradis V.
J Hepatol. 2022 Feb;76(2):343-352. doi: 10.1016/j.jhep.2021.09.034.

[Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.](#)

Calderaro J, Di Tommaso L, Maillé P, Beaufrère A, Nguyen CT, Heij L, Gnemmi V, Graham RP, Charlotte F, Chartier S, Wendum D, Vij M, Allende D, Diaz A, Fuster C, Rivière B, Herrero A, Augustin J, Evert K, Calvisi DF, Leow WQ, Leung HHW, Bednarsch J, Boleslawski E, Rela M, Chan AW, Forner A, Reig M, Pujals A, Favre L, Allaire M, Scatton O, Uguen A, Trépo E, Sanchez LO, Chatelain D, Rimmelink M, Boulagnon-Rombi C, Bazille C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Kather JN, Gouw ASH, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaïem R, Nault JC, Laurent A, Amaddeo G, Regnault H, de Martin E, Sempoux C, Navale P, Shinde J, Bacchuwar K, Westerhoff M, Lo RC, Sebbagh M, Guettier C, Lequoy M, Komuta M, Zioli M, Paradis V, Shen J, Caruso S.
J Hepatol. 2022 Dec;77(6):1586-1597. Doi: 10.1016/j.jhep.2022.07.019. Epub 2022 Aug 18.
PMID: 35987274

[Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study](#)

Eric Trépo 1, Stefano Caruso 2, Jie Yang 3, Sandrine Imbeaud 2, Gabrielle Couchy 2, Quentin Bayard 2, Eric Letouzé 2, Nathalie Ganne-Carrié 4, Christophe Moreno 5, Abderrahim Oussalah 6, Cyrille Féray 7, Jean Frédéric Blanc 8, Bruno Clément 9, Patrick Hillon 10, Jérôme Boursier 11, Valérie Paradis 12, Julien Calderaro 13, Viviane Gnemmi 14, Jean-Charles Nault 4, Jean-Louis Guéant 15, Jacques Devière 5, Isabelle Archambeaud 16, Carole Vitellius 11, Bruno Turlin 9, Jean-Pierre Bronowicki 17, Thierry Gustot 18, Angela Sutton 19; GENTHEP Consortium; Marianne Zioli 20, Pierre Nahon 4, Jessica Zucman-Rossi 21
Lancet Oncol
2022 Jan;23(1):161-171. Doi: 10.1016/S1470-2045(21)00603-3. Epub 2021 Dec 11

[Hepatocellular carcinoma hosts immature neurons and cholinergic tumors that correlate with adverse molecular features and outcomes](#)

Charlotte A. Hernandez, Claire Verzeroli, Ievgeniia Chicherova, Abud-José Farca-Luna, Laurie Tonon, Pascale Bellaud, Bruno Turlin, Alain Fautrel, Zuzana Macek-Jilkova, Thomas Decaens, Sandra Rebouissou, Alain Viari, Fabien Zoulim, Romain Parent
bioRxiv 2022.06.14.495889; doi: <https://doi.org/10.1101/2022.06.14.495889>

[Well-differentiated liver cancers reveal the potential link between ACE2 dysfunction and metabolic breakdown.](#)

Desquilles L, Cano L, Ghukasyan G, Mouchet N, Landreau C, Corlu A, et al.
Sci Rep. 2022; 12:1859

[Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis.](#)

Desert R, Ge X, Song Z, Han H, Lantvit D, Chen W, et al.
Hepatol Commun 2022; 6:692-709.

2021

[Two Metabolomics Phenotypes of Human Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease According to Fibrosis Severity.](#)

Buchard B, Teilhet C, Abeywickrama Samarakoon N, Massoulier S, Joubert-Zakeyh J, Blouin C, Reynes C, Sabatier R, Biesse- Martin AS, Vasson MP, Abergel A, Demidem A.
Metabolites. 2021 Jan 14;11(1):54. doi: 10.3390/metabo11010054.

[Metalloomic profile in non-cirrhotic hepatocellular carcinoma supports a phenomenon of metal metabolism adaptation in tumor cells.](#)

Cano L, Bertani S, Island ML, Cerapio JP, Ruiz E, Pineau P, Monbet V, Boudjema K, Taxa L, Casavilca-Zambrano S, Ropert M, Turlin B, Loréal O.
Sci Rep. 2021 Jul 9;11(1):14195. doi: 10.1038/s41598-021-93369-4.

[Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.](#)

Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Zioli M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, Zucman-Rossi J.
J Hepatol. 2021 May;74(5):1155-1166. doi: 10.1016/j.jhep.2020.11.052. Epub 2020 Dec 15.

[Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches.](#)

Dourthe C, Julien C, Di Tommaso S, Dupuy JW, Dugot-Senant N, Brochard A, Le Bail B, Blanc JF, Chiche L, Balabaud C, Bioulac- Sage P, Saltel F, Raymond AA.
Hepatology. 2021 Mar 23. doi: 10.1002/hep.31826. Online ahead of print.

2020

[Recurrent chromosomal rearrangements of *ROS1*, *FRK* and *IL6* activating *JAK/STAT* pathway in inflammatory hepatocellular adenomas.](#)

Bayard Q, Caruso S, Couchy G, Rebouissou S, Bioulac Sage P, Balabaud C, Paradis V, Sturm N, de Muret A, Guettier C, Bonsang B, Copie C, Letouzé E, Calderaro J, Imbeaud S, Nault JC, Zucman-Rossi J.
Gut. 2020 Sep;69(9):1667-1676. doi: 10.1136/gutjnl-2019-319790. Epub 2020 Jan 6.

[Polyploidy spectrum: a new marker in HCC classification.](#)

Bou-Nader M, Caruso S, Donne R, Celton-Morizur S, Calderaro J, Gentric G, Cadoux M, L'Hermitte A, Klein C, Guilbert T, Albuquerque M, Couchy G, Paradis V, Couty JP, Zucman-Rossi J, Desdouets C.
Gut. 2020 Feb;69(2):355-364. doi: 10.1136/gutjnl-2018-318021. Epub 2019 Apr 12.

[BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.](#)

Hirsch TZ, Negulescu A, Gupta B, Caruso S, Noblet B, Couchy G, Bayard Q, Meunier L, Morcrette G, Scoazec JY, Blanc JF, Amaddeo G, Nault JC, Bioulac-Sage P, Zioli M, Beaufrère A, Paradis V, Calderaro J, Imbeaud S, Zucman-Rossi J.
J Hepatol. 2020 May;72(5):924-936. doi: 10.1016/j.jhep.2019.12.006. Epub 2019 Dec 18.

[Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.](#)

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Zioli M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J.
Hepatology. 2020 Jan;71(1):164-182. doi: 10.1002/hep.30811. Epub 2019 Aug 12.

[Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.](#)

Job S, Rapoud D, Dos Santos A, Gonzalez P, Desterke C, Pascal G, Elarouci N, Ayadi M, Adam R, Azoulay D, Castaing D, Vibert E, Cherqui D, Samuel D, Sa Cuhna A, Marchio A, Pineau P, Guettier C, de Reyniès A, Faivre J.
Hepatology. 2020 Sep;72(3):965-981. doi: 10.1002/hep.31092. Epub 2020 Aug 16.

2019

[A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.](#)

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Bayard Q, Gustot T, Deviere J, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Zioli M, Zucman-Rossi J, Nault JC. **Hepatology**. 2019 Jul;70(1):231-240. doi: 10.1002/hep.30623. Epub 2019 Apr 25.

[Proteomic Landscape of Cholangiocarcinomas Reveals Three Different Subgroups According to Their Localization and the Aspect of Non-Tumor Liver.](#)

Le Faouder J, Gigante E, Léger T, Albuquerque M, Beaufrère A, Soubrane O, Dokmak S, Camadro JM, Cros J, Paradis V. **Proteomics Clin Appl**. 2019 Jan;13(1):e1800128. doi: 10.1002/prca.201800128. Epub 2018 Dec 19.

[Retrodifferentiation of Human Tumor Hepatocytes to Stem Cells Leads to Metabolic Reprogramming and Chemoresistance.](#)

Fekir K, Dubois-Pot-Schneider H, Désert R, Daniel Y, Glaise D, Rauch C, Morel F, Fromenty B, Musso O, Cabillic F, Corlu A. **Cancer Res**. 2019 Apr 15;79(8):1869-1883. doi: 10.1158/0008-5472.CAN-18-2110. Epub 2019 Mar 5.

2018

[Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection.](#)

Désert R¹, Rohart F², Canal F³, Sicard M¹, Desille M¹, Renaud S¹, Turlin B¹, Bellaud P¹, Perret C³, Clément B¹, Lê Cao KA², Musso O¹. **Hepatology**. 2017 Nov;66(5):1502-1518. doi: 10.1002/hep.29254. Epub 2017 Sep 26.

[Collision of hepatocellular nodules in vascular livers: a medical challenge](#)

Le Bail B, Chiche L, Balabaud C, Bioulac-Sage P.. **Clin Res Hepatol Gastroenterol** 2017 (in press)

[Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: A nosological and prognostic determinant](#)

Halgand B, Desterke C, Rivière L, Fallot G, Sebah M, Calderaro J, Bioulac-Sage P, Neuveut C, Buendia MA, Samuel D, Féray C.. **Hepatology** 2017 (in press)

[Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.](#)

Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J. **J Hepatol**. 2017 Oct;67(4):727-738.

[Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro.](#)

Rebouissou S, La Bella T, Rekik S, Imbeaud S, Calatayud AL, Rorh-Udilova N, Martin Y, Couchy G, Bioulac-Sage P, Grasl-Kraupp B, de Koning L, Ganne-Carrié N, Nault JC, Zioli M, Zucman-Rossi J. **Clin Cancer Res**. 2017 Feb 28. pii: clincanres.3118.2016. doi: 10.1158/1078-0432.CCR-16-3118. [Epub ahead of print]

[Germline and somatic DICER1 mutations in familial and sporadic liver tumors.](#)

Caruso S, Calderaro J, Letouzé E, Nault JC, Couchy G, Boulay A, Luciani A, Zafrani ES, Bioulac-Sage P, Seror O, Imbeaud S, Zucman-Rossi J. **J Hepatol**. 2017 Apr;66(4):734-742. doi: 10.1016/j.jhep.2016.12.010. Epub 2016 Dec 22.

[Malignant transformation of a \$\beta\$ -catenin inflammatory adenoma due to an S45 \$\beta\$ -catenin-activating mutation present 12 years before.](#)

Sempoux C, Bisig B, Couchy G, Balabaud C, Zucman-Rossi J, Bioulac-Sage P. **Hum Pathol**. 2017 Apr;62:122-125. doi: 10.1016/j.humpath.2016.10.004. Epub 2016 Oct 28.

[Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.](#)

Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP Investigators., Bioulac-Sage P, Letouzé E, Zucman-Rossi J. **Gastroenterology**. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7.

[CD44 is a key player in non-alcoholic steatohepatitis.](#)

Patouraux S, Rousseau D, Bonnafous S, Lebeauin C, Luci C, Canivet CM, Schneck AS, Bertola A, Saint-Paul MC, Iannelli A, Gugenheim J, Anty R, Tran A, Bailly-Maitre B, Gual P. **J Hepatol.** 2017 Mar 16. pii: S0168-8278(17)30137-X. doi: 10.1016/j.jhep.2017.03.003. [Epub ahead of print]

[Hepatocellular adenoma: Classification, variants and clinical relevance](#)

Bivouac-Sage P, Sempoux C, Balabaud C. **Semin Diagn Pathol.** 2017;34(2):112-125.

[Inflammatory hepatocellular adenoma with focal b-catenin mutation revealed on formalin fixed and paraffin-embedded tissue.](#)

Saldarriaga J, Bisig B, Couchy G, Castain C, Zucman-Rossi J, Balabaud C, Sempoux C, Bioulac-Sage P. **Histopathology** 2017 (in press)

[Whole genome sequencing reveals the dynamic interplay of risk factors, cellular processes and driver genes during hepatocarcinogenesis](#)

Letouzé E, Shinde J, Renault V, Couchy G, Blanc JF, Tubacher E, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Jessica Zucman-Rossi. **Nature Communications** 2017 (in press)

[Hepatocellular adenomas. Morphology and Genomics.](#)

Bivouac-Sage P, Sempoux C, Balabaud C. **Gastroenterol Clin N Am** 2017;

[Unexpected discovery of small HNF1a-inactivated hepatocellular adenoma in pathological specimens from patients resected for liver tumors](#)

Balabaud C, Laurent C, Le Bail B, Castain C, Possenti L, Frulio N, Chiche L, Blanc JF, Bioulac-Sage P. **Liver Intern**, 2017 (in press)

[Benign Hepatocellular Tumors. Practical Hepatic Pathology. A diagnostic approach](#)

Bivouac-Sage P, Frulio N, Balabaud C. Romil Saxena, Elsevier eds second edition, 2017, page 507-527

[Argininosuccinate synthase 1 \(ASS1\): a marker of unclassified hepatocellular adenoma and high bleeding risk.](#)

Henriet E, Abou Hammoud A, Dupuy J-W, Dartigues B, Ezzoukry Z, Dugot-Senant N, Leste Lasserre, Pallares-Lupon N, Nikolski M, Le Bail B, Blanc JF, Balabaud C, Bioulac-Sage P, Raymond AA, Saltel F. **Hepatology** 2017 (in press).

[Structure, Function, and Responses to Injury](#)

Crawford JM, Bioulac-Sage P, Hytiroglou P. **MacSween's Pathology of the Liver.** Burt A, Ferrell LD, Hübscher SG eds, Elsevier seventh Edition, 2017, page1-87

2017

[Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection.](#)

Désert R¹, Rohart F², Canal F³, Sicard M¹, Desille M¹, Renaud S¹, Turlin B¹, Bellaud P¹, Perret C³, Clément B¹, Lê Cao KA², Musso O¹. **Hepatology.** 2017 Nov;66(5):1502-1518. doi: 10.1002/hep.29254. Epub 2017 Sep 26.

[Collision of hepatocellular nodules in vascular livers: a medical challenge](#)

Le Bail B, Chiche L, Balabaud C, Bioulac-Sage P. **Clin Res Hepatol Gastroenterol** 2017 (in press)

[Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: A nosological and prognostic determinant](#)

Halgand B, Desterke C, Rivière L, Fallot G, Sebah M, Calderaro J, Bioulac-Sage P, Neuveut C, Buendia MA, Samuel D, Féray C. **Hepatology** 2017 (in press)

[Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.](#)

Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J. **J Hepatol.** 2017 Oct;67(4):727-738.

[Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro.](#)

Rebouissou S, La Bella T, Rekić S, Imbeaud S, Calatayud AL, Rorh-Udilova N, Martin Y, Couchy G, Bioulac-Sage P, Grasl-Kraupp B, de Koning L, Ganne-Carrie N, Nault JC, Zioli M, Zucman-Rossi J. **Clin Cancer Res.** 2017 Feb 28. pii: clincanres.3118.2016. doi: 10.1158/1078-0432.CCR-16-3118. [Epub ahead of print]

[Germline and somatic DICER1 mutations in familial and sporadic liver tumors.](#)

Caruso S, Calderaro J, Letouzé E, Nault JC, Couchy G, Boulai A, Luciani A, Zafrani ES, Bioulac-Sage P, Seror O, Imbeaud S, Zucman-Rossi J. **J Hepatol.** 2017 Apr;66(4):734-742. doi: 10.1016/j.jhep.2016.12.010. Epub 2016 Dec 22.

[Malignant transformation of a \$\beta\$ -catenin inflammatory adenoma due to an S45 \$\beta\$ -catenin-activating mutation present 12 years before.](#)

Sempoux C, Bisig B, Couchy G, Balabaud C, Zucman-Rossi J, Bioulac-Sage P. **Hum Pathol.** 2017 Apr;62:122-125. doi: 10.1016/j.humpath.2016.10.004. Epub 2016 Oct 28.

[Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.](#)

Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S, GENTHEP Investigators, Bioulac-Sage P, Letouzé E, Zucman-Rossi J. **Gastroenterology.** 2017 Mar;152(4):880-894.e6.

doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7.

[CD44 is a key player in non-alcoholic steatohepatitis.](#)

Patouraux S, Rousseau D, Bonnafous S, Lebeaupin C, Luci C, Canivet CM, Schneck AS, Bertola A, Saint-Paul MC, Iannelli A, Gugenheim J, Anty R, Tran A, Bailly-Maitre B, Gual P. **J Hepatol.** 2017 Mar 16. pii: S0168-8278(17)30137-X. doi: 10.1016/j.jhep.2017.03.003. [Epub ahead of print]

[Hepatocellular adenoma: Classification, variants and clinical relevance](#)

Bivouac-Sage P, Sempoux C, Balabaud C. **Semin Diagn Pathol.** 2017;34(2):112-125.

[Inflamatory hepatocellular adenoma with focal b-catenin mutation revealed on formalin fixed and paraffin-embedded tissue.](#)

Saldarriaga J, Bisig B, Couchy G, Castain C, Zucman-Rossi J, Balabaud C, Sempoux C, Bioulac-Sage P. **Histopathology** 2017 (in press)

[Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis.](#) Letouzé E,

Shinde J, Renault V, Couchy G, Blanc JF, Tubacher E, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Jessica Zucman-Rossi. **Nature Communications** 2017 (in press)

[Hepatocellular adenomas. Morphology and Genomics.](#)

Bivouac-Sage P, Sempoux C, Balabaud C. **Gastroenterol Clin N Am** 2017;

[Unexpected discovery of small HNF1a-inactivated hepatocellular adenoma in pathological specimens from patients resected for liver tumors](#)

Balabaud C, Laurent C, Le Bail B, Castain C, Possenti L, Frulio N, Chiche L, Blanc JF, Bioulac-Sage P. **Liver Intern**, 2017 (in press)

[Benign Hepatocellular Tumors. Practical Hepatic Pathology. A diagnostic approach](#)

Bivouac-Sage P, Frulio N, Balabaud C. Romil Saxena, Elsevier eds second edition, 2017, page 507-527 [Argininosuccinate](#)

[synthase 1 \(ASS1\): a marker of unclassified hepatocellular adenoma and high bleeding risk.](#) Henriot E, Abou Hammoud A,

Dupuy J-W, Dartigues B, Ezzoukry Z, Dugot-Senant N, Leste Lasserre, Pallares-Lupon N, Nikolski M, Le Bail B, Blanc JF,

Balabaud C, Bioulac-Sage P, Raymond AA, Saltel F. **Hepatology** 2017 (in press).

[Structure, Function, and Responses to Injury](#)

Crawford JM, Bioulac-Sage P, Hytioglou P. **MacSween's Pathology of the Liver.** Burt A, Ferrell LD, Hübscher SG eds, Elsevier seventh Edition, 2017, page1-87

2016

[Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation.](#)

Quaglia A, Alves VA, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Hytioglou P, Nakanuma Y, Paradis V, Snover DC, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ; International Liver Pathology Study Group. **Histopathology.** 2016 Jun;68(7):953-67.

[Liver transplantation for adenomatosis: European experience.](#)

Chiche L, David A, Adam R, Oliverius MM, Klempnauer J, Vibert E, Colledan M, Lerut J, Mazzafero VV, Di-Sandro S, Laurent C, Scuderi V, Suc B, Troisi R, Bachelier P, Dumortier J, Gugenheim J, Mabrut JY, Gonzalez-Pinto I, Pruvot FR, Le-Treut YP, Navarro F, Ortiz-de-Urbina J, Salamé E, Spada M, Bioulac-Sage P. **Liver Transpl.** 2016 Apr;22(4):516-26.

[Hepatocellular adenoma with malignant transformation in a patient with neonatal portal vein thrombosis.](#) Arrivé L,

Zucman-Rossi J, Ballardur P, Wendum D. **Hepatology.** 2016 Apr 4. doi: 10.1002/hep.28590.

[Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin.](#)

Guedj N, Vaquero J, Clapéron A, Mergey M, Chrétien Y, Paradis V, Fouassier L. **Histopathology.** 2016 Jan 21. doi: 10.1111/his.12931.

[e88689.IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans.](#)

Alzaid F, Lagadec F, Albuquerque M, Ballaire R, Orliaguet L, Hainault I, Blugeon C, Lemoine S, Lehuen A, Saliba DG, Udalova I A, Paradis V, Foufelle F, Venteclef N.

[TGF-β1 promotes linear invadosome formation in hepatocellular carcinoma cells, through DDR1 up-regulation and collagen I cross-linking.](#)

Ezzoukry Z, Henriot E, Piquet L, Boyé K, Bioulac-Sage P, Balabaud C, Couchy G, Zucman-Rossi J, Moreau V, Saltel F. **J Hepatol.** 2016 Jun;64(6):1199-202. doi: 10.1016/j.jhep.2016.03.009.

["Fibrous nests" in human hepatocellular carcinoma express a Wnt-induced gene signature associated with poor clinical outcome.](#)

Désert R, Mebarki S, Desille M, Sicard M, Lavergne E, Renaud S, Bergeat D, Sulpice L, Perret C, Turlin B, Clément B, Musso O. **Int J Biochem Cell Biol.** 2016 Dec;81(Pt A):195-207. doi: 10.1016/j.biocel.2016.08.017. Epub 2016 Aug 18.

[Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular Carcinoma.](#) Allain C,

Angenard G, Clément B, Coulouarn C. **Cancer Res.** 2016 Nov 1;76(21):6374-6381. Epub 2016 Sep 12.

[Genotype-phenotype correlation of CTNNB1 mutations reveals different \$\beta\$ -catenin activity associated with liver tumor progression.](#)

Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault JC, Couchy G, Laurent A, Balabaud C, Bioulac-Sage P, Zucman-Rossi J. **Hepatology**. 2016 Dec;64(6):2047-2061. doi: 10.1002/hep.28638. Epub 2016 Jun 11.

[De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas.](#)

Mebarki S, Désert R, Sulpice L, Sicard M, Desille M, Canal F, Dubois-Pot Schneider H, Bergeat D, Turlin B, Bellaud P, Lavergne E, Le Guével R, Corlu A, Perret C, Coulouarn C, Clément B, Musso O. **Oncotarget**. 2016 Jun 28;7(26):39026-39043. doi: 10.18632/oncotarget.9346.

[AAV2 and Hepatocellular Carcinoma.](#)

Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J. **Hum Gene Ther**. 2016 Mar;27(3):211-3. doi: 10.1089/hum.2016.002. No abstract available.

[Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.](#)

Calderaro J, Nault JC, Balabaud C, Couchy G, Saint-Paul MC, Azoulay D, Mehdaoui D, Luciani A, Zafrani ES, Bioulac-Sage P, Zucman-Rossi J. **Mod Pathol**. 2016 Jan;29(1):43-50. doi: 10.1038/modpathol.2015.119. Epub 2015 Oct 30.

[Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.](#)

Bergeat D, Fautrel A, Turlin B, Merdrignac A, Rayar M, Boudjema K, Coulouarn C, Sulpice L. **J Surg Res**. 2016 Jun 15;203(2):441-50. doi: 10.1016/j.jss.2016.03.044. Epub 2016 Mar 26.

[Gene expression profiling of the tumor microenvironment in human intrahepatic cholangiocarcinoma.](#)

Sulpice L, Desille M, Turlin B, Fautrel A, Boudjema K, Clément B, Coulouarn C. **Genom Data**. 2016 Jan 15;7:229-32. doi: 10.1016/j.gdata.2016.01.012. eCollection 2016 Mar.

[The rs3957357C>T SNP in GSTA1 Is Associated with a Higher Risk of Occurrence of Hepatocellular Carcinoma in European Individuals.](#)

Akhdar H, El Shamieh S, Musso O, Désert R, Joumaa W, Guyader D, Aninat C, Corlu A, Morel F. **PLoS One**. 2016 Dec 9;11(12):e0167543. doi: 10.1371/journal.pone.0167543. eCollection 2016

2015

[Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.](#)

Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J. **Nat Genet**. 2015 Oct;47(10):1187-93. doi: 10.1038/ng.3389. Epub 2015 Aug 24.

[Effects of TGF-beta signalling inhibition with galunisertib \(LY2157299\) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.](#)

Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, Benhadji KA, Raymond E, Faivre S, de Gramont A. **Oncotarget**. 2015 Aug 28;6(25):21614-27.

[Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.](#) Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. **Nat Genet**. 2015 May;47(5):505-11. doi: 10.1038/ng.3252. Epub 2015 Mar 30.

[Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease.](#)

Gentric G, Maillat V, Paradis V, et al. **J Clin Invest**. 2015 Mar 2;125(3):981-92. doi: 10.1172/JCI73957. [NRF2/KEAP1](#)

[and Wnt/ \$\beta\$ -catenin in the multistep process of liver carcinogenesis in humans and rats.](#)

Nault JC, Rebouissou S, Zucman Rossi J. **Hepatology**. 2015 Sep;62(3):677-9. doi: 10.1002/hep.27828. Epub 2015 Jun 9.

[Well-differentiated hepatocellular neoplasm of uncertain malignant potential.](#)

Balabaud C, Bioulac-Sage P, Ferrell L, Kakar S, Paradis V, Quaglia A, Sempoux C, Thung S, Zucman-Rossi J. **Hum Pathol**. 2015 Apr;46(4):634-5. doi: 10.1016/j.humpath.2014.10.029. Epub 2014 Dec 31.

[DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma.](#)

Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J, Imbeaud S, Letouzé E, Hernandez-Gea V, Cornella H, Pinyol R, Solé M, Fuster J, Zucman-Rossi J, Mazzaferro V, Esteller M, Llovet JM; HEPTROMIC Consortium. **Hepatology**. 2015 Jun;61(6):1945-56. doi: 10.1002/hep.27732. Epub 2015 Mar 18.

[Unique genomic profile of fibrolamellar hepatocellular carcinoma.](#)

Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesús M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM. **Gastroenterology**. 2015 Apr;148(4):806-18.e10. doi: 10.1053/j.gastro.2014.12.028. Epub 2014 Dec 31.

[Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPAR \$\alpha\$ expression.](#)

Loyer X, Paradis V, Héniqne C, Vion AC, Colnot N, Guerin CL, Devue C, On S, Scetbun J, Romain M, Paul JL, Rothenberg ME, Marcellin P, Durand F, Bedossa P, Prip-Buus C, Baugé E, Staels B, Boulanger CM, Tedgui A, Rautou PE. **Gut**. 2015 Sep 3. pii: gutjnl-2014-308883. doi: 10.1136/gutjnl-2014-308883.

[Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.](#)

Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. **J Hepatol**. 2015 Apr;62(4):848-54. doi: 10.1016/j.jhep.2014.11.005. Epub 2014 Nov 11.

2014

[Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC.](#) Fuks D,

Cauchy F, Fusco G, et al. **J Hepatol**. 2014 Sep;61(3):589-93. doi: 10.1016/j.jhep.2014.04.046.

[EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.](#)

Clapéron A, Mergéy M, Nguyen Ho-Boulidoires TH, et al. **J Hepatol**. 2014 Aug;61(2):325-32. doi: 10.1016/j.jhep.2014.03.033. Epub 2014 Apr 3.

[Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry.](#)

Le Faouder J, Laouirem S, Alexandrov T, et al. **Proteomics**. 2014 Apr;14(7-8):965-72. doi: 10.1002/pmic.201300463.

[In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin- \$\beta\$ 4 as markers of malignant intraductal pancreatic mucinous neoplasms.](#)

Rebours V, Le Faouder J, Laouirem S, et al. **Pancreatol**. 2014 Mar-Apr;14(2):117-24. doi: 10.1016/j.pan.2013.12.001. Epub 2013 Dec 17.

[Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.](#)

Malouf GG, Job S, Paradis V, et al. **Hepatology**. 2014 Jun;59(6):2228-37. doi: 10.1002/hep.27018. Epub 2014 Apr 30.

[Integrative quantitative proteomics unveils proteostasis imbalance in human hepatocellular carcinoma developed on nonfibrotic livers.](#)

Negróni L, Taouji S, Arma D, et al. **Mol Cell Proteomics**. 2014 Dec;13(12):3473-83. doi: 10.1074/mcp.M114.043174.

[Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.](#)

Nault JC, Calderaro J, Di Tommaso L, et al. **Hepatology**. 2014 Dec;60(6):1983-92. doi: 10.1002/hep.27372.

[Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas.](#)

Amadeo G, Cao Q, Ladeiro Y, et al. **Gut**. 2014 Jun 9. pii: gutjnl-2013-306228. doi: 10.1136/gutjnl-2013-306228.

[Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.](#)

Ahn SM, Jang SJ, Shim JH, et al. **Hepatology**. 2014 Dec;60(6):1972-82. doi: 10.1002/hep.27198. Epub 2014 Sep 22.

[Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.](#)

Pilati C, Letouzé E, Nault JC, et al. **Cancer Cell**. 2014 Apr 14;25(4):428-41. doi: 10.1016/j.ccr.2014.03.005.

[Overexpression of phosphatidylinositol 4-kinase type III \$\alpha\$ is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma.](#)

Ilboudo A, Nault JC, Dubois-Pot-Schneider H, et al. **BMC Cancer**. 2014 Jan 6;14:7. doi: 10.1186/1471-2407-14-7.

[Inflammatory cytokines promote the retrodifferentiation of tumor-derived hepatocyte-like cells to progenitor cells.](#)

Dubois-Pot-Schneider H, Fekir K, Coulouarn C, et al. **Hepatology**. 2014 Dec;60(6):2077-90. doi: 10.1002/hep.27353.

[Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma.](#)

Sulpice L, Rayar M, Turlin B, et al. **J Surg Res**. 2014 Nov;192(1):117-23. doi: 10.1016/j.jss.2014.05.017.

[ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ \$\beta\$ -catenin pathway.](#)

Calderaro J, Nault JC, Bioulac-Sage P, et al. **Virchows Arch**. 2014 Jan;464(1):53-60. doi: 10.1007/s00428-013-1515-0. Epub 2013 Nov 26.

2013

[Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma.](#)

Shukla R, Upton KR, Muñoz-Lopez M, et al. **Cell**. 2013 Mar 28;153(1):101-11. doi: 10.1016/j.cell.2013.02.032.

[Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic](#)

[cholangiocarcinoma.](#)

Sulpice L, Rayar M, Desille M, et al. **Hepatology**. 2013 Dec;58(6):1992-2000. doi: 10.1002/hep.26577. Epub 2013 Oct 17. [The ATPase activity of reptin is required for its effects on tumor cell growth and viability in hepatocellular carcinoma.](#)
Grigoletto A, Neaud V, Allain-Courtois et al. **Mol Cancer Res**. 2013 Feb;11(2):133-9. doi: 10.1158/1541-7786.MCR-12-0455. Epub 2012 Dec 10.

[ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ \$\beta\$ -catenin pathway.](#)

Calderaro J, Nault JC, Bioulac-Sage P, et al. **Virchows Arch**. 2013 Nov 26

[High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.](#)

Nault JC, Mallet M, Pilati C, et al. **Nat Commun**. 2013;4:2218.

[Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification.](#)

Balabaud C, Al-Rabih WR, Chen PJ, et al. **Int J Hepatol**. 2013;2013:268625. doi: 10.1155/2013/268625. Epub 2013 Apr 14. [A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.](#)

Nault JC, De Reyniès A, Villanueva A, et al. **Gastroenterology**. 2013 Jul;145(1):176-87. doi: 10.1053/j.gastro.2013.03.051.

[Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.](#) Calderaro J, Labrune P, Morcrette G, et al. **J Hepatol**. 2013 Feb;58(2):350-7. doi: 10.1016/j.jhep.2012.09.030. Epub 2012 Oct 6.

[A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma.](#)

Maurel M, Jalvy S, Ladeiro Y, et al. **Hepatology**. 2013 Jan;57(1):195-204. doi: 10.1002/hep.25994.

[Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas.](#)

Poté N, Alexandrov T, Le Faouder J, et al. **Hepatology**. 2013 Sep;58(3):983-94. doi: 10.1002/hep.26433. Epub 2013 Jul 30. [Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome.](#)

Paradis V, Albuquerque M, Mebarki M, et al. **Gut**. 2013 Jun;62(6):911-9. doi: 10.1136/gutjnl-2012-302091. Epub 2012 Sep 1. [Co-existence of inflammatory hepatocellular adenomas with HNF1 \$\alpha\$ inactivated adenomas: is there an association?](#)

Castain C, Sempoux C, Brunt EM, et al. **Histopathology**. 2013 Nov 15. doi: 10.1111/his.12326. [Epub ahead of print]

[Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas.](#)

Poté N, Alexandrov T, Le Faouder J, et al. **Hepatology**. 2013 Sep;58(3):983-94. doi: 10.1002/hep.26433. Epub 2013 Jul 30.

2012

[Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGF \$\beta\$ signaling pathways.](#)

Coulouarn C, Cavard C, Rubbia-Brandt L, et al. **Carcinogenesis**. 2012 Sep;33(9):1791-6. doi: 10.1093/carcin/bgs208. Epub 2012 Jun 13.

[Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.](#)

Guichard C, Amaddeo G, Imbeaud S, et al. **Nat Genet**. 2012 May 6;44(6):694-8. doi: 10.1038/ng.2256.

[Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma.](#)

Coulouarn C, Corlu A, Glaize D, et al. **Cancer Res**. 2012 May 15;72(10):2533-42. doi: 10.1158/0008-5472.CAN-11-3317. Epub 2012 Mar 14.

[Inhibition of Wnt/ \$\beta\$ -catenin signaling by a soluble collagen-derived frizzled domain interacting with Wnt3a and the receptors frizzled 1 and 8.](#)

Hendaoui I, Lavergne E, Lee HS, et al. **PLoS One**. 2012;7(1):e30601. doi: 10.1371/journal.pone.0030601. Epub 2012 Jan 27. [CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells.](#)

Monnier J, Boissan M, L'Helgoualc'h A, et al. **Eur J Cancer**. 2012 Jan;48(1):138-48. doi: 10.1016/j.ejca.2011.06.044. Epub 2011 Jul 19.

[Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.](#)

Yi P, Higa A, Taouji S, Bexiga et al. **Mol Cancer Ther**. 2012 Dec;11(12):2610-20. doi: 10.1158/1535-7163.MCT-12-0516. Epub 2012 Oct 5.

[Rnd3/RhoE Is down-regulated in hepatocellular carcinoma and controls cellular invasion.](#)

Grise F, Sena S, Bidaud-Meynard A, et al. **Hepatology**. 2012 Jun;55(6):1766-75. doi: 10.1002/hep.25568.

[Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs.](#)

Borel F, Han R, Visser A, Petry H, et al. **Hepatology**. 2012 Mar;55(3):821-32. doi: 10.1002/hep.24682. Epub 2012 Jan 13.

[Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes.](#)

Bioulac-Sage P, Cubel G, Taouji S, et al. **Am J Surg Pathol**. 2012 Nov;36(11):1691-9. doi: 10.1097/PAS.0b013e3182653ece. [KIF20A](#)

[mRNA and its product MKlp2 are increased during hepatocyte proliferation and hepatocarcinogenesis.](#)

Gasnereau I, Boissan M, Margall-Ducos G, et al. **Am J Pathol.** 2012 Jan;180(1):131-40. doi: 10.1016/j.ajpath.2011.09.040. Epub 2011 Nov 1.

[Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein.](#)

Studach LL, Menne S, Cairo S, et al. **Hepatology.** 2012 Oct;56(4):1240-51. doi: 10.1002/hep.25781.